Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: J Immunol. 2017 Mar 22;198(9):3536–3547. doi: 10.4049/jimmunol.1602087

Figure 9.

Figure 9

Effects of recombinant human IL-1β or IL-24 on primary human corneal epithelial cells (HCECs). (A) HCECs were treated with recombinant human IL-1β (50ng/ml). Cells were collected at 1h and 2h for qPCR analysis of SOCS3, IL-24, IL-1β, and IL-6. (B) HCECs were treated with recombinant human IL-24 (100ng/ml). Cells were collected at 1h and 2h for qPCR analysis of SOCS3, IL-1β, IL-24, and IL-6. Results are presented relative to those of untreated control cells, set as 1 (mean+s.e.m.). **P < 0.01, and ***P < 0.001 (ANOVA). Data are representative of three independent experiments.